Drugs / Neracorvir
Neracorvir
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04868981 | May 2021 → Feb 2022 | hepatitis B virus infection | Fujian Cosunter Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04386915 | May 2020 → May 2021 | hepatitis B virus infection | Fujian Cosunter Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT07709520 | Jul → Oct 2026 expected | chronic hepatitis B virus infection | Fujian Akeylink Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05637541 | Jan 2023 → Jul 2024 | chronic hepatitis B virus infection | Fujian Akeylink Biotechnology Co., Ltd. | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT07588009 | Jun 2026 → Jan 2028 expected | chronic hepatitis B virus infection | Fujian Akeylink Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07090759 | Jul 2025 → Dec 2026 expected | chronic hepatitis B virus infection | Fujian Akeylink Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Fujian Cosunter Pharmaceutical Co. Ltd | Results 国际权威医学期刊《柳叶刀-eClinicalMedicine》发表！广生堂核心蛋白调节剂GST-HG141（奈瑞可韦）II期研究成果获国际学术界认可 cosunter.com ↗
2025年8月3日，福建广生堂药业创新药控股子公司福建广生中霖生物科技有限公司的国产口服核心蛋白调节剂GST-HG141（英文通用名 “Neracorvir”，中文通用名 “奈瑞可韦”）的II期临床研究结果正式在线发表于国际顶级医学期刊《柳叶刀-eClinicalMedicine》。 |
| 2025-01-24 | Fujian Cosunter Pharmaceutical Co. Ltd | Results 广生堂在研乙肝新药GST-HG141奈瑞可韦 Ⅰb期临床试验结果成功发表于国际权威病毒学杂志《Virology Journal》 cosunter.com ↗
研究结果显示GST-HG141 在所有剂量下均表现出良好的安全性和耐受性 |
| 2024-12-15 | Fujian Cosunter Pharmaceutical Co. Ltd | Regulatory 广生堂药业乙肝治疗创新药奈瑞可韦GST-HG141纳入国家突破性治疗品种名单 cosunter.com ↗
福建广生堂药业创新药控股子公司福建广生中霖生物科技有限公司的乙肝治疗创新药GST-HG141（英文通用名 “Neracorvir”，中文通用名 “奈瑞可韦”）被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。 |
| 2022-03-14 | Fujian Cosunter Pharmaceutical Co. Ltd | Results 广生堂GST-HG141一期临床数据发布暨二期开发策略研讨会 cosunter.com ↗
会上，吉林大学第一医院I 期药物临床试验病房主任丁艳华教授 团队发布了 GST-HG141 一期临床结果， 结果 显示 GST-HG141 对于中国慢性乙肝患者具有良好的安全性和药效学、药代动力学特性， 该 试验获得 的 积极结果支持 GST-HG141 继续开展 II 期临床试验。 |
| 2021-02-05 | Fujian Cosunter Pharmaceutical Co. Ltd | Results APASL热评丨牛俊奇教授：新型HBV CAM（GST-HG141）具有良好的体内外抗病毒活性 cosunter.com ↗
结果显示，GST-HG141 明显抑制HepG2.2.15细胞中的 HBV DNA ，其 EC50 值为8.16±3.65 nmol/L (表 1)。 |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Fujian Cosunter Pharmaceutical Co. Ltd | 国际权威医学期刊《柳叶刀-eClinicalMedicine》发表！广生堂核心蛋白调节剂GST-HG141（奈瑞可韦）II期研究成果获国际学术界认可 cosunter.com ↗ |
| 2025-05-25 | Fujian Cosunter Pharmaceutical Co. Ltd | GST-HG141（奈瑞可韦）III期临床试验第一次研究者会议在杭州成功召开 cosunter.com ↗ |
| 2025-01-24 | Fujian Cosunter Pharmaceutical Co. Ltd | 广生堂在研乙肝新药GST-HG141奈瑞可韦 Ⅰb期临床试验结果成功发表于国际权威病毒学杂志《Virology Journal》 cosunter.com ↗ |
| 2024-12-15 | Fujian Cosunter Pharmaceutical Co. Ltd | 广生堂药业乙肝治疗创新药奈瑞可韦GST-HG141纳入国家突破性治疗品种名单 cosunter.com ↗ |
| 2022-03-14 | Fujian Cosunter Pharmaceutical Co. Ltd | 广生堂GST-HG141一期临床数据发布暨二期开发策略研讨会 cosunter.com ↗ |
| 2021-02-05 | Fujian Cosunter Pharmaceutical Co. Ltd | APASL热评丨牛俊奇教授：新型HBV CAM（GST-HG141）具有良好的体内外抗病毒活性 cosunter.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neracorvir | “GST-HG141（Neracorvir）for Combination Therapy” NCT07090759 ↗ |
| Known as | GST-HG141 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07709520 ↗ |
| Known as | Nairecovir | “GST-HG141 (Nairecovir)” NCT07588009 ↗ |
| Known as | Nairevir | “GST-HG141 (Nairevir)” NCT07588009 ↗ |
| Known as | nerlecovir | “GST-HG141 (nerlecovir, 50 mg BID)” NCT07588009 ↗ |
| Modality | Other / unclassified | “GST-HG141 is a novel, potent and selective HBV CAM” NCT07709520 ↗ |
| Route | Oral | “Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses” NCT04868981 ↗ |